Catabasis Pharmaceuticals Inc. Common Stock
(NASDAQ:CATB)
Description
Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.
CATB Overview
None
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$32.8000 |
Previous Close Volume |
29020 |